By Dani Kass ( August 5, 2021, 10:27 PM EDT) -- A split Federal Circuit panel has once again revived a $235 million verdict against Teva for inducing infringement of GlaxoSmithKline's heart disease drug Coreg, although the panel's revised decision Thursday warned that the ruling shouldn't have a broader impact on generic drugs with skinny labels....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.